omniture

WuXi PharmaTech Schedules Second Quarter 2008 Earnings Release on Wednesday, August 13, 2008

2008-07-25 03:54 1764

Earnings Conference Call to be Held on August 14, 2008 at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong)

SHANGHAI, China, July 25 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or “the Company”), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release unaudited financial results for the second quarter 2008 after the US market close on Wednesday, August 13, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations section of its website at http://www.wuxipharmatech.com.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on Thursday, August 14, 2008 to discuss its 2008 second quarter financial results and recent business activities. The conference call may be accessed by calling:

Toll Free Toll

United States 800-289-0528 913-981-5522

China, Northern Region 10-800-714-0970

China, Southern Region 10-800-140-0945

Hong Kong 800-965-503

United Kingdom 0-800-051-7166

A telephone replay will be available shortly after the call until September 14, 2008 at (US) 888-203-1112/ (HK) 800-901-108 / (China, Southern Region) 10-800-140-1178 / (China, Northern Region) +1-719-457-0820 / (UK) +0808-101-1153. Passcode: 2740550.

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech’s website at http://www.wuxipharmatech.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Investor Contact:

Dr. Hai Mi, Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd.

Tel: +86-21-5046-3726

Email: ir@pharmatechs.com

Investor Relations (US):

Mahmoud Siddig, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com

Investor Relations (HK):

Ruby Yim, Managing Director

Taylor Rafferty

Tel: +852-3196-3712

Email: Pharmatechs@taylor-rafferty.com

Media Contact:

John Dudzinsky, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com

Source: WuXi PharmaTech (Cayman) Inc.
Related Stocks:
NYSE:WX
collection